RGC logo

REGENCELL BIOSCIENCE HOLDING

RGCNASDAQ
🏆 #1682 by market capUS Equity
$921.42▲ $46.81 (+5.08%)
Simulated price
🔔
Track RGC
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 5.1%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$3.07B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
76
Good
No chart data available for RGC.

Trading Snapshot

Day Range
$911.70 – $934.65
52-Week Range
$4.51 – $69.00
Volume
$3.09B
Avg Volume
$3.91B
Shares Outstanding
495.5M
Next Earnings
Nov 26, 2026

Fundamentals Snapshot

Annual Revenue
$320M
Last Q Revenue
$83M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-0.01
Dividend Yield
—
Dilution (1yr)
+0.0%

Why Investors Own RGC

  • ✓High-growth profile — revenue up +16.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 65% gross margin and 25% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

RGC logo

REGENCELL BIOSCIENCE HOLDING

RGC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$4M▼ −20.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −18.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
494.5M▲ +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▲ +$2M YoY
StockOtter · stockotter.space

About REGENCELL BIOSCIENCE HOLDING

Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$927.34
▲ +0.6% Upside
High Target$1,066.10
Low Target$834.95
Based on 25 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

REGENCELL BIOSCIENCE HOLDING tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift RGC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

REGENCELL BIOSCIENCE HOLDING announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.